G1SecL05: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Moazzam Khan (talk | contribs) No edit summary |
Moazzam Khan (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
LYMErix, implemented in 1998 by the FDA,is a noninfectious vaccine that uses recombinant ospA expressed by ''Escherichia coli'' absorbed into an aluminum hydroxide adjuvant to stimulate immune response during injection. The formation of specific IgG anti- ospA antibodies including those directed towards the epitope LA-2that resulted following vaccination aimed at traveling to the tick’s mid-gut in order to interact with ''B.burgdorferi'', preventing transmission of Lyme disease to host. | LYMErix, implemented in 1998 by the FDA,is a noninfectious vaccine that uses recombinant ospA expressed by ''Escherichia coli'' absorbed into an aluminum hydroxide adjuvant to stimulate immune response during injection. The formation of specific IgG anti- ospA antibodies including those directed towards the epitope LA-2that resulted following vaccination aimed at traveling to the tick’s mid-gut in order to interact with ''B.burgdorferi'', preventing transmission of Lyme disease to host. | ||
[[Image:LYMErix.jpg| | [[Image:LYMErix.jpg|center|thumb|Retail Packaging of LYMErix™]] | ||
Vaccine efficiency was evaluated by immunizing mice with LYMErix and using ELISA to measure their serum antibody response to ospA. In 1996, clinical trials conducted in highly endemic areas of the United States with sample size exceeding 10,000 subjects, LYMErix was found to confer protective immunity to ''B. burgdorferi'' in 76% of adults and 100% of children with only mild and transient short term effects. | Vaccine efficiency was evaluated by immunizing mice with LYMErix and using ELISA to measure their serum antibody response to ospA. In 1996, clinical trials conducted in highly endemic areas of the United States with sample size exceeding 10,000 subjects, LYMErix was found to confer protective immunity to ''B. burgdorferi'' in 76% of adults and 100% of children with only mild and transient short term effects. | ||
